What's in Japan Blood Products Organization's pipeline?

Japan Blood Products Organization has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Japan Blood Products Organization's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/japan-blood-products-organization.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Japan Blood Products Organization — Portfolio Competitive Intelligence Brief

Japan Blood Products Organization pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Placebo of GB-0998	Placebo of GB-0998	phase 3
GB-0998	GB-0998	phase 3	Recombinant C1-inhibitor replacement therapy	C1-inhibitor (C1-INH)	Immunology / Rare Disease

Therapeutic area mix

Immunology / Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Japan Blood Products Organization:

Cite this brief

Drug Landscape (2026). Japan Blood Products Organization — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/japan-blood-products-organization. Accessed 2026-05-16.